2024年四季度以来，A股市场走出了一轮结构性回暖行情，市场情绪逐步修复，投资机会在多条主线中 交替演绎。根据同花顺最新统计，截至9月24日的过去一年间，沪深300指数累计上涨36.22%，而同期 主动偏股型基金指数(932055)涨幅高达53.71%，显著跑赢大盘。这一数据不仅反映出主动管理型基金整 体业绩的强劲反弹，也凸显出基金经理在震荡市中的选股能力与策略执行力。 在对过去一年全市场主动权益类基金(包括股票型与混合型基金，剔除偏债混合、股债平衡、指数及指 数增强产品)的全面梳理中，我们发现：在全市场超4300只产品中，仅有58只基金实现了超过150%的收 益率，堪称"头部中的头部"。而其中，基金经理赵强所管理的三只产品悉数入选，成为本轮行情中极少 数能够实现"全系领先"的投资代表，展现出卓越的策略一致性与业绩爆发力。 实力验证：老将执舵，以持续业绩见证价值 赵强先生，一位拥有22年从业经验的资深战将，自2003年踏入基金行业，先后在华安基金、国金基金、 英大基金、中欧基金等机构担任投研要职，积累了完整的牛熊周期经验与多策略管理能力。他自2014年 起管理公募基金，2015年兼任专户投资，兼具公募的体系化 ...

Group 1 - The "Future Star of Science and Technology" report was released at the Jiangsu Industry-University-Research Cooperation Conference, highlighting 80 companies recognized for their innovative capabilities [1] - Jiangsu and Beijing each have 21 companies on the list, making them the top regions in terms of representation [1] - The report categorizes companies as "Future Stars" based on their cutting-edge and disruptive technological innovations, showcasing early-stage potential for commercialization and high value [1][3] Group 2 - The 80 companies are distributed across ten sectors, with AI and robotics, innovative pharmaceuticals, and innovative medical devices being the top three, accounting for 53.8% of the total [2] - In the AI and robotics sector, four companies from Jiangsu made the list, while four companies from Jiangsu were also recognized in the innovative pharmaceuticals sector [2] - The majority of the 80 companies are in the seed or early startup phase, with a total financing amount exceeding 10 billion yuan, averaging 1.5 million yuan per company [3]

Core Insights - A total of 80 "Future Stars of Science and Technology" companies have been selected nationwide, with Jiangsu province having 21 companies, tying with Beijing for the highest number [1][3] - The "Future Stars" are defined as technology startups that demonstrate cutting-edge and disruptive technological innovation capabilities, showcasing technological leadership, commercialization potential, and high value at an early stage [1][4] Company Summary - The list of 21 companies from Jiangsu includes sectors such as integrated circuits, innovative medical devices, and innovative pharmaceuticals [2] - Notable companies include Nanjing Zhong'an Semiconductor Equipment Co., Jiangsu Bochuang Biotechnology Co., and Nanjing Mainoway Pharmaceutical Technology Co. [2] Industry Overview - The 80 selected companies span 10 major fields, with AI and robotics, innovative pharmaceuticals, and innovative medical devices being the top three sectors, accounting for a cumulative share of 53.8% [3] - In the AI and robotics sector, four Jiangsu companies made the list, while in innovative pharmaceuticals and medical devices, four and two companies respectively were recognized [3] Regional Distribution - The 80 companies are distributed across 13 provinces (municipalities and special administrative regions), with Beijing and Jiangsu each having 21 companies, followed by Guangdong with 10 [3] - Within Jiangsu, Suzhou has 11 companies and Nanjing has 7, ranking second and third respectively, while Wuxi and Changzhou have 2 and 1 company [3] Financing and Growth Potential - The "Future Stars" concept was introduced based on years of research on high-growth companies, with a focus on those addressing key national strategic directions through innovative technologies [4] - All 80 companies have secured financing, with a total funding amount exceeding 10 billion yuan, averaging 1.5 million yuan per company [4]

Investment Rating - The industry investment rating is "Overweight (Maintain)" [2] Core Viewpoints - The innovative pharmaceutical and medical device market continues to thrive, with an increase in the prosperity of segmented tracks. The Shanghai Composite Index rose by 2.37%, while the pharmaceutical and biological sector increased by 3.08%, ranking 10th among 31 primary sub-industries. The pharmaceutical sector has shown strong recovery and continuity, aligning with previous predictions that declines would be short-lived and shallow [4][8][5]. - The market remains focused on innovative pharmaceuticals and medical devices, with significant events catalyzing the sector. Key highlights include a price increase of up to 170% for Eli Lilly's weight loss drug Mounjaro in the UK and the announcement of pivotal clinical trial results for a dual-target antibody by CanSino Biologics [4][8][5]. - Recommendations for investment focus on specific segments such as GLP-1 drugs, second-generation IO companies, and innovative medical devices, with notable companies identified for potential growth [4][8][5]. Summary by Sections Industry Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biological industry [2]. Market Dynamics - The pharmaceutical sector has shown a year-to-date return of 25.02%, outperforming the Shanghai Composite Index by 18.22 percentage points. The sector's valuation is currently at 27.0 times PE, with a premium of 32.9% compared to the overall A-share market [5][16][8]. Key Company Performance - Notable companies recommended for investment include WuXi Biologics, 3SBio, Changchun High-tech, and others, with their respective stock performances highlighted [2][26][25]. Sector Trends - The report emphasizes the ongoing trend of innovation in pharmaceuticals and medical devices, with specific attention to the GLP-1 drug market and second-generation IO companies, suggesting a rotation of investment opportunities within these segments [4][8][5].

Group 1 - The core viewpoint of the article highlights that Shenzhen Silicon-based Bionic Technology Co., Ltd. has been awarded the "Best Innovative Medical Device Company of the Year" at the 9th Medical Health Investment Excellence List by Haoyue Capital, recognizing its outstanding performance in the innovative medical device sector [1][3] - The "Medical Health Investment Excellence List" is a prestigious evaluation created by Haoyue Capital, focusing on the comprehensive strength of investment institutions in the medical health industry, including activity levels, transaction volumes, return performance, and post-investment empowerment [3][4] - Silicon-based Bionic was founded in 2015 and specializes in blood glucose monitoring, utilizing implantable medical hardware technology and AI algorithms to innovate and promote continuous monitoring products globally [4][5] Group 2 - The company has a workforce of nearly 700, led by scientists from prestigious institutions such as Tsinghua University, Peking University, Caltech, Princeton, and the University of Washington, showcasing a strong research and operational management background [4][5] - Its flagship product, the Silicon-based Dynamic CGM, is the second globally and the first in China to use second-generation glucose sensor technology, achieving the highest sales among domestic CGM products for several consecutive years [4][5] - The company has made significant investments in R&D, participating in key national projects and being recognized as a "National High-Performance Medical Device Innovation Center" and a "Potential Technology Unicorn Enterprise" in Shenzhen [5][6] Group 3 - The Chinese medical health industry is experiencing a structural recovery in 2025, with increased financing activity and significant milestone transactions, indicating a shift towards high-quality, international, and value-driven medical innovation [5][6] - Silicon-based Bionic aims to uphold its core value of "Innovating Medical Technology, Serving Public Health" and aspires to become a global leader in chronic disease management innovative medical devices [6]

Core Viewpoint - The innovative drug industry continues to strengthen in Q2, significantly outperforming similar risk assets like AI and robotics sectors, attracting high market attention [1][2]. Policy Factors - The National Medical Insurance Administration (NMI) encourages innovation, leading to favorable policies for innovative drugs and a notable acceleration in domestic approvals [2]. - The introduction of a multi-layered insurance payment system is expected to enhance the market for innovative drugs, transitioning from a reliance on basic medical insurance to a dual-driven model of commercial and basic insurance [4]. Performance Factors - Many large innovative drug companies reported profits or are on the verge of profitability in their Q1 reports, boosting market confidence in the sector [2]. - The innovative drug sector has seen a significant increase in the number and value of outbound deals, with Chinese innovative drugs accounting for over half of global transactions [2]. Market Outlook - The period from 2025 to 2028 is anticipated to be crucial for Chinese innovative drug companies as they collectively enter a profitability phase, marking a potential turning point for the sector [3]. - 2025 is projected to be a pivotal year for revenue growth, with around 80% of A-share and Hong Kong-listed innovative drug companies expected to see a surge in product revenues [3]. Investment Strategy - The investment strategy focuses on identifying high-quality companies with favorable valuation through a multi-dimensional comparison of business models, competitiveness, and performance [2]. - The management of the Ping An Medical Health Mixed Securities Investment Fund has achieved a remarkable performance of 57.41% in the first half of the year, with the net value recently surpassing its previous peak in 2021 [1][5].

Group 1 - The pharmaceutical sector has experienced a nearly five-year correction since a strong rally from 2019 to 2020, but investment is gradually warming up this year driven by innovative drug concepts [1] - Wan Minyuan, a fund manager with a medical background, believes that the most difficult times for the pharmaceutical industry may have passed, with a relatively optimistic outlook on the sector's performance [1][4] - The investment strategy of Wan Minyuan emphasizes safety and a contrarian approach, focusing on buying when the market is less interested and selling when it is more enthusiastic [2][3] Group 2 - Wan Minyuan's investment philosophy is rooted in maintaining a high win rate by ensuring correct decisions outweigh incorrect ones, which is crucial for sustainable and predictable returns [2][3] - The pharmaceutical sector is expected to see improvements in 2025 due to the gradual resolution of multiple factors that have constrained its performance, including favorable policy changes [4][5] - Key drivers for long-term growth in the pharmaceutical industry remain unchanged, such as population aging, changes in disease patterns, and the supply of innovative technologies [5] Group 3 - Wan Minyuan focuses on companies with stable operations and emphasizes the importance of prudent financial management, avoiding overly aggressive accounting practices [3][5] - The investment strategy includes a long holding period for core positions, with a disciplined approach to selling based on specific criteria such as valuation bubbles and significant deviations from expected company performance [5][6] - Wan Minyuan identifies three main investment opportunities in the pharmaceutical sector: innovative drugs and medical devices, recovery in pharmaceutical consumption, and low price-to-book ratio assets [6][7] Group 4 - The interest in innovative drugs is growing, with an increase in upfront payments for licensing deals, although A-share market valuations for innovative drugs are currently high [7] - Wan Minyuan is also expanding investment horizons beyond the pharmaceutical sector, looking at domestic demand and technology sectors, particularly in undervalued assets in the Hong Kong market [7]